Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Corticosteroid treatment in severe COVID-19 pneumonia : two cases and literature review

Coronavirus disease 2019 (COVID-19) pneumonia, firstly reported in Wuhan, Hubei province, China, has rapidly spread around the world with high mortality rate among critically ill patients. The use of corticosteroids in COVID-19 remains a major controversy. Available evidences are inconclusive. According to WHO guidance, corticosteroids are not recommended to be used unless for another reason. Chinese Thoracic Society (CTS) proposes an expert consensus statement that suggests taking a prudent attitude of corticosteroid usage. In our clinical practice, we do not use corticosteroids routinely; only low-to-moderate doses of corticosteroids were given to several severely ill patients prudently. In this paper, we will present two confirmed severe COVID-19 cases admitted to isolation wards in Optical Valley Campus of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. We will discuss questions related to corticosteroids usages

Year of Publication: 2020
Contained in: Clinical rheumatology Vol. 39, No. 7 (2020), p. 2031-2037
All journal articles: Search for all articles in this journal
Language: English
Contributors: Dai, Jinghong | Author
Xiong, Yali
Li, Hui
Qian, Yajun
Xu, Ying
Xu, Qingqing
Yan, Xin
Tang, Jian
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
Case Reports
Corticosteroids
HRCT
Journal Article
Review
Severe COVID-19 pneumonia
Additional Keywords: *Coronavirus Infections
*Pandemics
*Pneumonia, Viral
Adult
Aged
Antiviral Agents
Betacoronavirus
Clinical Decision-Making
Glucocorticoids
Humans
Lung
Male
Oxygen Inhalation Therapy
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome
ISSN: 1434-9949
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 24.06.2020
Date Revised 24.06.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32451729
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1007/s10067-020-05172-7
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03953nma a2200841 c 4500
001 NLM311213251
003 DE-601
005 20200625213739.0
007 cr uuu---uuuuu
008 200526s2020 000 0 eng d
024 7 |a 10.1007/s10067-020-05172-7  |2 doi 
028 5 2 |a pubmed20n1245.xml 
035 |a (DE-599)NLM32451729 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Dai, Jinghong 
245 1 0 |a Corticosteroid treatment in severe COVID-19 pneumonia  |h Elektronische Ressource  |b two cases and literature review 
300 |a Online-Ressource 
500 |a Date Completed 24.06.2020 
500 |a Date Revised 24.06.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Coronavirus disease 2019 (COVID-19) pneumonia, firstly reported in Wuhan, Hubei province, China, has rapidly spread around the world with high mortality rate among critically ill patients. The use of corticosteroids in COVID-19 remains a major controversy. Available evidences are inconclusive. According to WHO guidance, corticosteroids are not recommended to be used unless for another reason. Chinese Thoracic Society (CTS) proposes an expert consensus statement that suggests taking a prudent attitude of corticosteroid usage. In our clinical practice, we do not use corticosteroids routinely; only low-to-moderate doses of corticosteroids were given to several severely ill patients prudently. In this paper, we will present two confirmed severe COVID-19 cases admitted to isolation wards in Optical Valley Campus of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. We will discuss questions related to corticosteroids usages 
611 2 7 |a Case Reports  |2 gnd 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Review  |2 gnd 
653 2 |a Adult  |6 D000328 
653 2 |a Aged  |6 D000368 
653 2 |a Antiviral Agents  |6 D000998  |a administration & dosage  |6 Q000008 
653 2 |a Betacoronavirus  |6 D000073640  |a isolation & purification  |6 Q000302 
653 2 |a Clinical Decision-Making  |6 D000066491 
653 2 |a *Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a physiopathology  |6 Q000503  |a therapy  |6 Q000628 
653 2 |a Glucocorticoids  |6 D005938  |a *administration & dosage  |6 Q000008 
653 2 |a Humans  |6 D006801 
653 2 |a Lung  |6 D008168  |a diagnostic imaging  |6 Q000000981 
653 2 |a Male  |6 D008297 
653 2 |a Oxygen Inhalation Therapy  |6 D010102  |a methods  |6 Q000379 
653 2 |a *Pandemics  |6 D058873 
653 2 |a *Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a diagnosis  |6 Q000175  |a etiology  |6 Q000209  |a physiopathology  |6 Q000503  |a therapy  |6 Q000628 
653 2 |a Severity of Illness Index  |6 D012720 
653 2 |a Tomography, X-Ray Computed  |6 D014057  |a *methods  |6 Q000379 
653 2 |a Treatment Outcome  |6 D016896 
655 7 |a COVID-19  |2 gnd 
655 7 |a Corticosteroids  |2 gnd 
655 7 |a HRCT  |2 gnd 
655 7 |a Severe COVID-19 pneumonia  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Glucocorticoids  |2 gnd 
689 0 0 |A f  |a Case Reports 
689 0 1 |A f  |a Journal Article 
689 0 2 |A f  |a Review 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a Corticosteroids 
689 1 2 |a HRCT 
689 1 3 |a Severe COVID-19 pneumonia 
689 1 |5 DE-601 
689 2 0 |a Antiviral Agents 
689 2 1 |a Glucocorticoids 
689 2 |5 DE-601 
700 1 |a Xiong, Yali 
700 1 |a Li, Hui 
700 1 |a Qian, Yajun 
700 1 |a Xu, Ying 
700 1 |a Xu, Qingqing 
700 1 |a Yan, Xin 
700 1 |a Tang, Jian 
773 0 8 |i in  |t Clinical rheumatology  |g Vol. 39, No. 7 (2020), p. 2031-2037  |q 39:7<2031-2037  |w (DE-601)NLM012613126  |x 1434-9949 
856 4 1 |u http://dx.doi.org/10.1007/s10067-020-05172-7  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 39  |j 2020  |e 7  |b 25  |c 07  |h 2031-2037